PharmiNews

The Directory of Pharma Companies and News

IGEM Therapeutics

IGEM is a UK immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer. Unlike immunoglobulin G (IgG), IgE has evolved to kill tissue-dwelling multicellular parasites endowing it with several key features that make it ideal for the treatment of solid tumours.

Pre-clinical proof of concept has been obtained with two different IgE antibodies both showing significantly greater efficacy versus IgG comparators in a variety of rodent cancer models. IGEM is building a portfolio of IgE antibody candidates targeting folate receptor alpha, HER2, EGFR, PD-L1 and CSPG4. The company is also developing a novel antibody platform technology based on protein and glyco-engineering of the epsilon constant region of IgE.

IGEM is a spin out of King’s College London and has access to the world class expertise in the lab of Dr Sophia Karagiannis at KCL.

Category:
Category:

0 results
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.